Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines total debt 2017–2026What is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
Revolution Medicines's total debt was 639.10M USD on 30 September 2026, up 303.3% on a year before. At the end of fiscal year 2025 it was 158.70M USD.
Last updated 8 Nov 2026 · Next report 24 Feb 2027
Total debt
Growth
| Fiscal year | Period ending | Total debt | Growth | Cash and short-term investments | Net cash | Debt to equity |
|---|---|---|---|---|---|---|
| Latest quarter | 30 Sept 2026 | 639.10M | +303.32% | 3.65B | 3.01B | 0.27 |
| FY2025 | 31 Dec 2025 | 158.70M | +16.83% | 2.03B | 1.87B | 0.10 |
| FY2024 | 31 Dec 2024 | 135.84M | +54.47% | 2.29B | 2.15B | 0.06 |
| FY2023 | 31 Dec 2023 | 87.94M | +36.97% | 1.85B | 1.77B | 0.05 |
| FY2022 | 31 Dec 2022 | 64.21M | -3.64% | 644.94M | 580.74M | 0.09 |
| FY2021 | 31 Dec 2021 | 66.63M | +104.00% | 577.05M | 510.42M | 0.11 |
| FY2020 | 31 Dec 2020 | 32.66M | — | 440.74M | 408.08M | 0.07 |
| FY2019 | 31 Dec 2019 | 0.00 | -100.00% | 122.76M | 122.76M | 0.00 |
| FY2018 | 31 Dec 2018 | 147.00K | — | 69.59M | 69.44M | 0.00 |
| FY2017 | 31 Dec 2017 | 0.00 | — | 9.08M | 9.08M | 0.00 |
| Quarter | Period ending | Total debt | Growth on a year before | Cash and short-term investments | Net cash | Debt to equity |
|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 639.10M | +303.32% | 3.65B | 3.01B | 0.27 |
| Q2 FY2026 | 30 Jun 2026 | 641.93M | +383.43% | 3.94B | 3.30B | 0.25 |
| Q1 FY2026 | 31 Mar 2026 | 437.27M | +225.49% | 1.91B | 1.47B | 0.29 |
| Q4 FY2025 | 31 Dec 2025 | 158.70M | +16.83% | 2.03B | 1.87B | 0.10 |
| Q3 FY2025 | 30 Sept 2025 | 158.46M | +82.76% | 1.93B | 1.77B | 0.10 |
| Q2 FY2025 | 30 Jun 2025 | 132.79M | +51.91% | 2.14B | 2.00B | 0.07 |
| Q1 FY2025 | 31 Mar 2025 | 134.34M | +52.61% | 2.10B | 1.97B | 0.06 |
| Q4 FY2024 | 31 Dec 2024 | 135.84M | +54.47% | 2.29B | 2.15B | 0.06 |
| Q3 FY2024 | 30 Sept 2024 | 86.71M | +37.96% | 1.55B | 1.46B | 0.06 |
| Q2 FY2024 | 30 Jun 2024 | 87.41M | +38.19% | 1.59B | 1.50B | 0.05 |
| Q1 FY2024 | 31 Mar 2024 | 88.03M | +38.42% | 1.70B | 1.62B | 0.05 |
| Q4 FY2023 | 31 Dec 2023 | 87.94M | +36.97% | 1.85B | 1.77B | 0.05 |
| Q3 FY2023 | 30 Sept 2023 | 62.85M | -3.61% | 813.20M | 750.35M | 0.08 |
| Q2 FY2023 | 30 Jun 2023 | 63.26M | -2.61% | 909.49M | 846.23M | 0.07 |
| Q1 FY2023 | 31 Mar 2023 | 63.60M | -3.52% | 909.80M | 846.20M | 0.07 |
| Q4 FY2022 | 31 Dec 2022 | 64.21M | -3.64% | 644.94M | 580.74M | 0.09 |
| Q3 FY2022 | 30 Sept 2022 | 65.20M | +105.12% | 655.01M | 589.81M | 0.10 |
| Q2 FY2022 | 30 Jun 2022 | 64.95M | +99.90% | 461.43M | 396.48M | 0.13 |
| Q1 FY2022 | 31 Mar 2022 | 65.91M | +106.02% | 518.75M | 452.84M | 0.12 |
| Q4 FY2021 | 31 Dec 2021 | 66.63M | +104.00% | 577.05M | 510.42M | 0.11 |
| Q3 FY2021 | 30 Sept 2021 | 31.79M | -4.77% | 608.66M | 576.87M | 0.05 |
| Q2 FY2021 | 30 Jun 2021 | 32.49M | -4.61% | 646.32M | 613.83M | 0.05 |
| Q1 FY2021 | 31 Mar 2021 | 31.99M | +195.20% | 681.59M | 649.60M | 0.04 |
| Q4 FY2020 | 31 Dec 2020 | 32.66M | — | 440.74M | 408.08M | 0.07 |
| Q3 FY2020 | 30 Sept 2020 | 33.38M | +21,159.87% | 466.14M | 432.76M | 0.07 |
| Q2 FY2020 | 30 Jun 2020 | 34.06M | — | 325.45M | 291.38M | 0.09 |
| Q1 FY2020 | 31 Mar 2020 | 10.84M | — | 347.95M | 337.11M | 0.03 |
| Q4 FY2019 | 31 Dec 2019 | 0.00 | -100.00% | 122.76M | 122.76M | 0.00 |
| Q3 FY2019 | 30 Sept 2019 | 157.00K | — | 136.29M | 136.13M | 0.00 |
| Q1 FY2019 | 31 Mar 2019 | 0.00 | — | 69.59M | 69.59M | 0.00 |
| Q4 FY2018 | 31 Dec 2018 | 147.00K | — | 69.59M | 69.44M | 0.00 |
Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.
Total debt counts commercial paper, term debt and lease liabilities.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Balance sheet
Common questions about Revolution Medicines's debt
Source: Financial Modeling PrepVerified against SEC filings